JP2009161554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009161554A5 JP2009161554A5 JP2009055839A JP2009055839A JP2009161554A5 JP 2009161554 A5 JP2009161554 A5 JP 2009161554A5 JP 2009055839 A JP2009055839 A JP 2009055839A JP 2009055839 A JP2009055839 A JP 2009055839A JP 2009161554 A5 JP2009161554 A5 JP 2009161554A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- group
- disease
- pharmaceutical composition
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000027744 congestion Diseases 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011953 Decreased activity Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 230000009858 acid secretion Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 230000008369 airway response Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 0 *C(c1ccc(C(*)(C2)CC2C(N(*)*)=O)cc1)N(*)* Chemical compound *C(c1ccc(C(*)(C2)CC2C(N(*)*)=O)cc1)N(*)* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73099605P | 2005-10-27 | 2005-10-27 | |
| US60/730,996 | 2005-10-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008537213A Division JP4319245B2 (ja) | 2005-10-27 | 2006-10-16 | ヒスタミン−３受容体拮抗薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009161554A JP2009161554A (ja) | 2009-07-23 |
| JP2009161554A5 true JP2009161554A5 (https=) | 2009-10-08 |
| JP5064427B2 JP5064427B2 (ja) | 2012-10-31 |
Family
ID=37776539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008537213A Expired - Fee Related JP4319245B2 (ja) | 2005-10-27 | 2006-10-16 | ヒスタミン−３受容体拮抗薬 |
| JP2009055839A Expired - Fee Related JP5064427B2 (ja) | 2005-10-27 | 2009-03-10 | ヒスタミン−３受容体拮抗薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008537213A Expired - Fee Related JP4319245B2 (ja) | 2005-10-27 | 2006-10-16 | ヒスタミン−３受容体拮抗薬 |
Country Status (39)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| EP2124933B1 (en) * | 2007-01-22 | 2012-10-17 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| WO2008108445A1 (ja) | 2007-03-07 | 2008-09-12 | Takeda Pharmaceutical Company Limited | ベンゾオキサゼピン誘導体およびその用途 |
| SA08290520B1 (ar) | 2007-08-22 | 2012-02-22 | استرازينيكا ايه بي | مشتقات سيكلو بروبيل أميد وتركيبات صيدلية تحتوي عليها لعلاج حالة مرضية سببها مستقبلات هيستامين h3 |
| CN101939306A (zh) * | 2007-12-07 | 2011-01-05 | 美国辉瑞有限公司 | 反式-n-异丁基-3-氟-3-[3-氟-4-(吡咯烷-1-基-甲基)-苯基]环丁烷甲酰胺的甲苯磺酸盐 |
| BRPI0913057A2 (pt) | 2008-05-08 | 2015-10-13 | Evotec Ag | azetidinas e ciclobutanos como antagonistas de receptor de histamina h3 |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| RU2012139082A (ru) | 2010-02-18 | 2014-03-27 | Астразенека Аб | Способы получения производных циклопропиламида и связанных с ними промежуточных соединений |
| EP2691393B1 (en) | 2011-03-31 | 2016-09-14 | Pfizer Inc | Novel bicyclic pyridinones |
| WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| ES2605565T3 (es) | 2011-08-31 | 2017-03-15 | Pfizer Inc | Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| ES2585262T3 (es) | 2012-05-04 | 2016-10-04 | Pfizer Inc | Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2 |
| WO2014001973A1 (en) | 2012-06-29 | 2014-01-03 | Pfizer Inc. | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS |
| CA2882389A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2014091352A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| WO2014125394A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| CN105121439A (zh) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 |
| ES2742078T3 (es) | 2013-10-04 | 2020-02-13 | Pfizer | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa |
| JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン |
| DK3126361T3 (da) | 2014-04-01 | 2020-01-02 | Pfizer | Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer |
| PE20170327A1 (es) | 2014-04-10 | 2017-04-21 | Pfizer | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| PL3177624T3 (pl) | 2014-08-06 | 2019-09-30 | Pfizer Inc. | Związki imidazopirydazynowe |
| MX368391B (es) | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
| EP3766885B1 (en) | 2015-06-17 | 2022-05-25 | Pfizer Inc. | Tricyclic compounds and their use as phosphodiesterase inhibitors |
| KR102161364B1 (ko) | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 |
| WO2017051276A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
| WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
| EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| SG11201806383TA (en) | 2016-02-23 | 2018-09-27 | Pfizer | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
| WO2018002760A1 (en) | 2016-07-01 | 2018-01-04 | Pfizer Inc. | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
| EP3592740B1 (en) | 2017-03-10 | 2022-02-09 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
| WO2018163066A1 (en) | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
| CN110997693A (zh) | 2017-06-07 | 2020-04-10 | 阿德克斯公司 | τ聚集抑制剂 |
| BR112019026955A2 (pt) | 2017-06-22 | 2020-06-30 | Pfizer Inc. | derivados de di-hidro-pirrolo-piridina |
| US11453701B2 (en) | 2017-08-18 | 2022-09-27 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| EP4219464A1 (en) | 2018-03-23 | 2023-08-02 | Pfizer Inc. | Piperazine azaspiro derivaves |
| EP4297868A4 (en) | 2021-02-23 | 2025-01-08 | Hoth Therapeutics, Inc. | USE OF APREPITANT TO TREAT ALZHEIMER'S |
| CN116514645A (zh) * | 2023-04-08 | 2023-08-01 | 绍兴上虞华伦化工有限公司 | 二氟-4溴苯甲醛及其制备工艺 |
| WO2025145091A1 (en) | 2023-12-29 | 2025-07-03 | Pfizer Inc. | Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6559140B2 (en) * | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| JP2004532834A (ja) | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| US7671047B2 (en) * | 2002-06-19 | 2010-03-02 | Sanofi-Aventis Deutschland Gmbh | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| JP2004131497A (ja) * | 2002-09-18 | 2004-04-30 | Satoshi Shuto | シスシクロプロパン誘導体 |
| DK1651615T3 (da) * | 2003-07-29 | 2010-05-25 | High Point Pharmaceuticals Llc | Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander |
| AU2004274309B2 (en) * | 2003-09-22 | 2010-04-08 | Msd K.K. | Novel piperidine derivative |
| EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
| SI1735278T1 (sl) * | 2004-04-01 | 2010-05-31 | Lilly Co Eli | Agenti histamin h receptorja priprava in terapevtska uporaba |
| US7456164B2 (en) * | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) * | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| JP2008543923A (ja) | 2005-06-22 | 2008-12-04 | ファイザー・プロダクツ・インク | ヒスタミン−３受容体アンタゴニスト |
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| EP2124933B1 (en) * | 2007-01-22 | 2012-10-17 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
-
2006
- 2006-10-13 US US11/549,175 patent/US8158673B2/en not_active Expired - Fee Related
- 2006-10-16 GE GEAP200610660A patent/GEP20104937B/en unknown
- 2006-10-16 AP AP2008004401A patent/AP2403A/xx active
- 2006-10-16 DK DK06809114.9T patent/DK1951660T3/da active
- 2006-10-16 SI SI200631724T patent/SI1951660T1/sl unknown
- 2006-10-16 WO PCT/IB2006/002977 patent/WO2007049123A1/en not_active Ceased
- 2006-10-16 HR HRP20140061TT patent/HRP20140061T1/hr unknown
- 2006-10-16 PL PL06809114T patent/PL1951660T3/pl unknown
- 2006-10-16 JP JP2008537213A patent/JP4319245B2/ja not_active Expired - Fee Related
- 2006-10-16 EA EA200800946A patent/EA013602B1/ru not_active IP Right Cessation
- 2006-10-16 BR BRPI0617797-2A patent/BRPI0617797A2/pt not_active IP Right Cessation
- 2006-10-16 NZ NZ566488A patent/NZ566488A/en not_active IP Right Cessation
- 2006-10-16 KR KR1020087009991A patent/KR101025358B1/ko not_active Expired - Fee Related
- 2006-10-16 RS RSP-2008/0173A patent/RS20080173A/sr unknown
- 2006-10-16 CA CA2621323A patent/CA2621323C/en not_active Expired - Fee Related
- 2006-10-16 UA UAA200802656A patent/UA88719C2/ru unknown
- 2006-10-16 CN CN2006800399763A patent/CN101296898B/zh not_active Expired - Fee Related
- 2006-10-16 EP EP06809114.9A patent/EP1951660B1/en active Active
- 2006-10-16 AU AU2006307645A patent/AU2006307645B2/en not_active Ceased
- 2006-10-16 ES ES06809114.9T patent/ES2444370T3/es active Active
- 2006-10-16 PT PT68091149T patent/PT1951660E/pt unknown
- 2006-10-16 RS RS20140034A patent/RS53153B/sr unknown
- 2006-10-20 NL NL1032713A patent/NL1032713C2/nl not_active IP Right Cessation
- 2006-10-24 PE PE2006001288A patent/PE20070720A1/es not_active Application Discontinuation
- 2006-10-25 AR ARP060104658A patent/AR056879A1/es active IP Right Grant
- 2006-10-25 GT GT200600471A patent/GT200600471A/es unknown
- 2006-10-25 UY UY29882A patent/UY29882A1/es not_active Application Discontinuation
- 2006-10-26 TW TW095139560A patent/TWI318206B/zh not_active IP Right Cessation
- 2006-10-26 DO DO2006000239A patent/DOP2006000239A/es unknown
- 2006-10-26 HN HN2006036385A patent/HN2006036385A/es unknown
-
2008
- 2008-02-28 IL IL189866A patent/IL189866A/en not_active IP Right Cessation
- 2008-04-02 TN TNP2008000150A patent/TNSN08150A1/fr unknown
- 2008-04-09 ZA ZA200803130A patent/ZA200803130B/xx unknown
- 2008-04-15 EC EC2008008373A patent/ECSP088373A/es unknown
- 2008-04-23 CU CU20080069A patent/CU23806B7/es not_active IP Right Cessation
- 2008-04-23 CR CR9910A patent/CR9910A/es not_active Application Discontinuation
- 2008-04-24 MY MYPI20081265A patent/MY145001A/en unknown
- 2008-04-25 MA MA30879A patent/MA29888B1/fr unknown
- 2008-04-28 NI NI200800132A patent/NI200800132A/es unknown
- 2008-05-16 NO NO20082264A patent/NO20082264L/no not_active Application Discontinuation
-
2009
- 2009-03-10 JP JP2009055839A patent/JP5064427B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-09 US US13/415,944 patent/US8389743B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009161554A5 (https=) | ||
| NO20082264L (no) | Histamin-3 reseptorantagonister | |
| JP2013542937A5 (https=) | ||
| WO2007088450A3 (en) | Chromane antagonist of the h-3 receptor | |
| WO2007105053A3 (en) | Tetralines antagonists of the h-3 receptor | |
| MX2009007782A (es) | Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma. | |
| ATE488496T1 (de) | Histamin-3-rezeptorantagonisten | |
| WO2007063385A3 (en) | Spirocyclic amine histamine-3 receptor antagonists | |
| WO2007138431A3 (en) | Azabicyclic ether histamine-3 antagonists | |
| JP2016500111A5 (https=) | ||
| JP2010514715A5 (https=) | ||
| JP2012515724A5 (https=) | ||
| JP2008513516A5 (https=) | ||
| JP2010514716A5 (https=) | ||
| JP2012255002A5 (https=) | ||
| JP2008513498A5 (https=) | ||
| JP2017518323A5 (https=) | ||
| JP2011500696A5 (https=) | ||
| JP2015505301A5 (https=) | ||
| JP2011500694A5 (https=) | ||
| JP2009510097A5 (https=) | ||
| CN103833736A (zh) | 一种阿伐那非的制备方法 | |
| WO2018141854A1 (en) | Piperazine derivatives for influenza virus inhibition | |
| JP2017521489A5 (https=) | ||
| JP2010517991A5 (https=) |